TABLE 5.

Literature data about RFS according to primary colorectal cancer (CRC) localization after metastasectomy of liver-only metastases.

Primary tumor localization	Ref no	N	Colon	Longer RFS	p	p	Preop	Sync	Postop	Follow-up a months
			%	NLR (SII) cut-off	Univ	Multiv	%	%	%
CRC
	3, 26	586	NA	>5	0.272	-	23	38	27	>6
	6	440	NA	<5	<0.001	<0.001	11	33	>33	24
	8	247	NA	<5	0.77	-	-	-	-	20
	13	169	NA	<2.5	0.09	0.347	100	72	76	34.6
	14	140	NA	<2.4	0.033	0.609	100	71	74	33
	16	92	NA	<5	0.047	0.022	76	0	100	27.1 b
COLON cancer
	25	98	100	<2.5	0.044	0.029	-	0	-	35.2 b
	Our study	67	100	<2	0.004	0.03	76	10	73	46.5
				(<535)	0.005	0.229
>50% of patients with COLON cancer
	9	575	78	≤5	0.104	-	86	66	90	37
	11	452	56	<2.6	0.163	-	63	53	74	28
				(≤517)	0.068	-
	4	343	58	<2.5	0.017	-	58	49	-	49
	5	295	60	<2	<0.001?	0.001	19	78	37	63.2
	12	283	66	(≤0.0135)	0.003	0.005	51	58	77	35.4
	31	231	67	≤3	0.049	0.06	76	35	72	73.2
	30	197	62	<3	0.284	0.617	26	57	-	-
	15	183	57	<2.3	ns	-	100	85	78	36.3
	29	150	58	<4.63	0.017	0.452	39	63	73	36
	28	182	70	>3	0.939	-	19	65	91	32.5 b
	27	128	79 c	<1.71	ns	-	74	63	-	45
	32	130	54	≤5	0.044	0.03	16	38	26	44 b
>50% of patients with RECTAL cancer
	17	83	24	<1.94	0.026	0.006	29	100	100	-
	7, 33	174	46	<5	0.008	ns	42	0	39	36
RECTAL cancer
	Our study	103	0	≥ 2.42	<0.001	<0.001	64	10	72	59.8
				(≥ 792)	<0.001	0.002

CRC, colorectal cancer; multiv, multivariate; NA, not available; ns, non-significant; Postop, postoperative treatment; Preop, preoperative treatment; Ref, reference; RFS, relapse-free survival; SII, systemic immune-inflammation index; Sync, synchronous; univ, univariate.

^aMedian.

^bAverage.

^cPersonal communication.